Combined antihypertensive and lipid-lowering treatment (Q35838501)

10 August 2017

1 reference

title

Combined antihypertensive and lipid-lowering treatment (English)

1 reference

10 August 2017

Maurizio Cesari

1

1 reference

PubMed ID

15257865

10 August 2017

Achille C Pessina

series ordinal

2

1 reference

10 August 2017

1 August 2004

1 reference

Current Hypertension Reports

10 August 2017

1 reference

10 August 2017

6

1 reference

10 August 2017

4

1 reference

10 August 2017

300-306

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-004-0025-5

10 August 2017

0 references

cites work

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1007%2FS11906-004-0025-5

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-004-0025-5

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-004-0025-5

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-004-0025-5

Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-004-0025-5

Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-004-0025-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

1 reference

12 December 2020

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

12 December 2020

Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension

1 reference

12 December 2020

Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators

1 reference

12 December 2020

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

Hypertension treatment and control in five European countries, Canada, and the United States

1 reference

12 December 2020

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

12 December 2020

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

1 reference

12 December 2020

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)

1 reference

12 December 2020

Cellular antioxidant effects of atorvastatin in vitro and in vivo

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice

1 reference

12 December 2020

Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden

1 reference

12 December 2020

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

1 reference

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Lipid management in diabetic patients: lessons from prevention trials

1 reference

12 December 2020

Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women

1 reference

12 December 2020

The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness

1 reference

12 December 2020

Under Treatment with Lipid-Lowering Drugs of High-Risk Coronary Heart Disease Patients of the GENICA Study

1 reference

12 December 2020

Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).

1 reference

12 December 2020

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

12 December 2020

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

1 reference

12 December 2020

Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia

1 reference

12 December 2020

HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.

1 reference

12 December 2020

Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group

1 reference

12 December 2020

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

1 reference

12 December 2020

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Risk stratification in hypertension: new insights from the Framingham Study

1 reference

12 December 2020

HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins

1 reference

12 December 2020

An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study

1 reference

12 December 2020

Contributions of the Framingham Study to the conquest of coronary artery disease

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats

1 reference

12 December 2020

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

1 reference

12 December 2020

10.1007/S11906-004-0025-5

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15257865